Before & After the Whistle Blows, an Ounce of Prevention is Worth a Pound of Legal Fees

A federal court issued a temporary stay of its ruling vacating the $100,000 H-1B fee, leaving the fee’s status uncertain pending First Circuit review.

In a series of major industry milestones, this week it was announced that the investigational drug Exilby, a standardized full-spectrum extract from a proprietary cannabis strain, has received marketing authorization from Germany for the treatment of chronic low back pain with a neuropathic component while late last month the United States Food & Drug Administration granted the medicine a Breakthrough Therapy Designation intended to expedite the development and evaluation of the drug. It is positioned as the first non-opiate chronic pain treatment of its kind worldwide.

On May 19, 2026, the Securities and Exchange Commission proposed two sets of amendments—one expanding the accessibility of smaller reporting companies to financing opportunities and the other simplifying the reporting framework for public companies.